Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: A pilot study

International Journal of COPD

Volumn 9, Issue , 2014, Pages 745-751

  Donohue, James F ^a   Herje, Nancy ^b   Crater, Glenn ^b   Rickard, Kathleen ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Aerocrine Inc   (United States)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Fractional exhaled nitric oxide; Inhaled corticosteroids

Indexed keywords

FRACTIONAL EXHALED NITRIC OXIDE; NITRIC OXIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NOMENCLATURE; OBSERVATIONAL STUDY; PILOT STUDY; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING; SPIROMETRY; VERY ELDERLY; BREATH ANALYSIS; CLINICAL TRIAL; EXHALATION; LUNG; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; SEVERITY OF ILLNESS INDEX; UNITED STATES; VITAL CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; EXHALATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; MIDDLE AGED; NITRIC OXIDE; NORTH CAROLINA; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; SEVERITY OF ILLNESS INDEX; SMOKING; SPIROMETRY; VITAL CAPACITY;

EID: 84904424817     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S44552     Document Type: Review

References (23)

1. The Global Strategy for the Diagnosis, Management and Prevention of COPD [webpage on the Internet]. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www. goldcopd. org/. Accessed April 22, 2014.
2. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomized controlled trial. Eur Respir J. 2007; 29(5): 906-913.
3. Alving K, Malinovschi A. Basic aspects of exhaled nitric oxide. In: Horvath I, de Jongste JC, editors. Exhaled Biomarkers. European Respiratory Society Monographs; 2010: 1-31.
4. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011; 184(5): 602-615.
5. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005; 26(2): 319-338.
6. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124(2): 474-481.
7. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009; 64(8): 728-735.
8. Beeh KM, Kornmann O, Beier J, Ksoll M, Buhl R. Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. Respir Med. 2004; 98(7): 591-597.
9. Tashkin DP, Celli B, Decramer M, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008; 31(4): 742-750.
10. Ramsdell JW, Nachtwey FJ, Moser KM. Bronchial hyperreactivity in chronic obstructive bronchitis. Am Rev Respir Dis. 1982; 126(5): 829-832.
11. Soter S, Barta I, Antus B. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation. 2013; 36(5): 1178-1185.
12. Fujimoto K, Kubo K, Yamamoto H, Yamaguchi S, Matsuzawa Y. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest. 1999; 115(3): 697-702.
13. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998; 158(5 Pt 1): 1511-1517.
14. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2000; 356(9240): 1480-1485.
15. Antus B, Barta I, Horvath I, Csiszer E. Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology. 2010; 15(3): 472-477.
16. Kunisaki KM, Rice KL, Janoff EN, Rector TS, Niewoehner DE. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. Ther Adv Respir Dis. 2008; 2(2): 55-64.
17. Akamatsu K, Matsunaga K, Sugiura H, et al. Improvement of airflow limitation by fluticasone propionate/salmeterol in chronic obstructive pulmonary disease: what is the specific marker? Front Pharmacol. 2011; 2: 36.
18. Zietkowski K, Kucharewicz I, Bodzenta-Lukaszyk A. The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease. Respir Med. 1999; 99(7): 816-824.
19. Zeiger RS, Schatz M, Zhang F, et al. Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids. J Allergy Clin Immunol. 2011; 128(2): 412-414.
20. Syk J, Malinovschi A, Johansson G, et al. Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial. J Allergy Clin Immunol Pract. 2013; 1(6): 639-648.
21. Donohue JF, Jain N. Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates. Respir Med. 2013; 107(7): 943-952.
22. Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med. 1995; 152(2): 609-612.
23. Barnes PJ, Dweik RA, Gelb AF, et al. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2010; 138(3): 682-692.